Profile
Jose Olague worked as a Director of Manufacturing Engineering & Maintenance at Intarcia Therapeutics, Inc. and as a Director of Manufacturing & Engineering at Avinger, Inc. He also served as the Vice President of Engineering at Alpha Teknova, Inc. from 2020 to 2023.
Mr. Olague obtained an undergraduate degree from Instituto Tecnológico de Ciudad Juárez.
Former positions of Jose Olague
| Companies | Position | End |
|---|---|---|
| ALPHA TEKNOVA, INC. | Chief Tech/Sci/R&D Officer | 01/09/2023 |
| AVINGER, INC. | Corporate Officer/Principal | - |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
Training of Jose Olague
| Instituto Tecnológico de Ciudad Juárez | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ALPHA TEKNOVA, INC. | Health Technology |
| AVINGER, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Jose Olague
